Clinical trial · Interventional
a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4
NCT00130858CI-TRIAL-00002188completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase II Study to evaluate the response on two blocks of topotecan and carboplatin
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma, Soft Tissue | Soft Tissue Sarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Topotecan | Drug | Topotecan | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Response according to RECIST criteria
Secondary outcomes (3)
- measure
- Toxicity
- measure
- Overall-Survival
- measure
- Event-free-survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Soft tissue sarcoma chemosensible, stage IV * age \< 21 * measurable tumor lesions Exclusion Criteria: * Lack of cooperation by the patient * no willingness of follow-up examinations * participation on another clinical trial at the same time * death due to the sickness within four weeks
References
Publications (0)
Data not yet available
No reference posted for this study.